Shareholder analysis


Shares issued

As at 31 August 2021, the number of ordinary shares in issue was 69,121,949.

Major shareholders

As at 31 August 2021, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company.
No of ordinary shares%
Balderton Capital III, LP (1)6,813,1969.9
Blind Trust (Richard Sharp)4,447,0006.4
Credit Suisse3,937,1965.7
Chelverton Asset Management3,889,3915.6
Dr Adam M Hill (2)3,537,5395.1
Genostics Company Ltd3,335,6594.8
Mr Timothy Brian Bunting2,956,7174.3
UBS Securities2,682,8713.9
Hargreaves Lansdown Asset Management2,408,9413.5
  1. Mr Bunting is a partner of Balderton Capital (UK) LLP the investment adviser to Balderton Capital Partners III, LP.
  2. Dr Hill is Chief Executive Officer of Oncimmune and holds 46,677 shares and 3,490,862 options to acquire shares in the Company. The percentage holding has been calculated based on the current number of ordinary shares in issue.

Director shareholdings

No of sharesNo of share optionsNo of warrants
Tim Bunting2,956,717--
Dr Adam M Hill46,6773,490,862-
Meinhard Schmidt31,0001,076,705226,250

Shares not in public hands

In accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 31 August 2021, 22.02% of the Company’s AIM securities was not in public hands.

Restrictions on transfer of Aim Securities

There are no restrictions on the transfer of securities.

UK City Code on takeovers and mergers

Oncimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers.

Details of other exchanges or trading platforms

Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms.

Page last updated: 22nd September 2021